Advanced search
1 file | 753.76 KB

Emerging evidence for CHFR as a cancer biomarker : from tumor biology to precision medicine

(2014) CANCER AND METASTASIS REVIEWS. 33(1). p.161-171
Author
Organization
Abstract
Novel insights in the biology of cancer have switched the paradigm of a "one-size-fits-all" cancer treatment to an individualized biology-driven treatment approach. In recent years, a diversity of biomarkers and targeted therapies has been discovered. Although these examples accentuate the promise of personalized cancer treatment, for most cancers and cancer subgroups no biomarkers and effective targeted therapy are available. The great majority of patients still receive unselected standard therapies with no use of their individual molecular characteristics. Better knowledge about the underlying tumor biology will lead the way toward personalized cancer treatment. In this review, we summarize the evidence for a promising cancer biomarker: checkpoint with forkhead and ring finger domains (CHFR). CHFR is a mitotic checkpoint and tumor suppressor gene, which is inactivated in a diverse group of solid malignancies, mostly by promoter CpG island methylation. CHFR inactivation has shown to be an indicator of poor prognosis and sensitivity to taxane-based chemotherapy. Here we summarize the current knowledge of altered CHFR expression in cancer, the impact on tumor biology and implications for personalized cancer treatment.
Keywords
CHFR promoter methylation, Predictive biomarker, CPG ISLAND HYPERMETHYLATION, RING-FINGER DOMAIN, POLO-LIKE KINASE-1, COLORECTAL-CANCER, PROMOTER HYPERMETHYLATION, GASTRIC-CANCER, EPIGENETIC INACTIVATION, STRESS CHECKPOINT, Taxane sensitivity, MITOTIC CHECKPOINT PROTEIN, CELL LUNG-CANCER

Downloads

  • Derks 2014 CMR 33 1 161.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 753.76 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Derks, Sarah, Arjen HG Cleven, Veerle Melotte, Kim M Smits, Johann C Brandes, Nilofer Azad, Wim Van Criekinge, Adriaan P de Bruïne, James G Herman, and Manon van Engeland. 2014. “Emerging Evidence for CHFR as a Cancer Biomarker : from Tumor Biology to Precision Medicine.” Cancer and Metastasis Reviews 33 (1): 161–171.
APA
Derks, S., Cleven, A. H., Melotte, V., Smits, K. M., Brandes, J. C., Azad, N., Van Criekinge, W., et al. (2014). Emerging evidence for CHFR as a cancer biomarker : from tumor biology to precision medicine. CANCER AND METASTASIS REVIEWS, 33(1), 161–171.
Vancouver
1.
Derks S, Cleven AH, Melotte V, Smits KM, Brandes JC, Azad N, et al. Emerging evidence for CHFR as a cancer biomarker : from tumor biology to precision medicine. CANCER AND METASTASIS REVIEWS. 2014;33(1):161–71.
MLA
Derks, Sarah, Arjen HG Cleven, Veerle Melotte, et al. “Emerging Evidence for CHFR as a Cancer Biomarker : from Tumor Biology to Precision Medicine.” CANCER AND METASTASIS REVIEWS 33.1 (2014): 161–171. Print.
@article{5936645,
  abstract     = {Novel insights in the biology of cancer have switched the paradigm of a {\textacutedbl}one-size-fits-all{\textacutedbl} cancer treatment to an individualized biology-driven treatment approach. In recent years, a diversity of biomarkers and targeted therapies has been discovered. Although these examples accentuate the promise of personalized cancer treatment, for most cancers and cancer subgroups no biomarkers and effective targeted therapy are available. The great majority of patients still receive unselected standard therapies with no use of their individual molecular characteristics. Better knowledge about the underlying tumor biology will lead the way toward personalized cancer treatment. In this review, we summarize the evidence for a promising cancer biomarker: checkpoint with forkhead and ring finger domains (CHFR). CHFR is a mitotic checkpoint and tumor suppressor gene, which is inactivated in a diverse group of solid malignancies, mostly by promoter CpG island methylation. CHFR inactivation has shown to be an indicator of poor prognosis and sensitivity to taxane-based chemotherapy. Here we summarize the current knowledge of altered CHFR expression in cancer, the impact on tumor biology and implications for personalized cancer treatment.},
  author       = {Derks, Sarah and Cleven, Arjen HG and Melotte, Veerle and Smits, Kim M and Brandes, Johann C and Azad, Nilofer and Van Criekinge, Wim and de Bru{\"i}ne, Adriaan P and Herman, James G and van Engeland, Manon},
  issn         = {0167-7659},
  journal      = {CANCER AND METASTASIS REVIEWS},
  keyword      = {CHFR promoter methylation,Predictive biomarker,CPG ISLAND HYPERMETHYLATION,RING-FINGER DOMAIN,POLO-LIKE KINASE-1,COLORECTAL-CANCER,PROMOTER HYPERMETHYLATION,GASTRIC-CANCER,EPIGENETIC INACTIVATION,STRESS CHECKPOINT,Taxane sensitivity,MITOTIC CHECKPOINT PROTEIN,CELL LUNG-CANCER},
  language     = {eng},
  number       = {1},
  pages        = {161--171},
  title        = {Emerging evidence for CHFR as a cancer biomarker : from tumor biology to precision medicine},
  url          = {http://dx.doi.org/10.1007/s10555-013-9462-4},
  volume       = {33},
  year         = {2014},
}

Altmetric
View in Altmetric
Web of Science
Times cited: